These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9353856)

  • 1. Clinical heterogeneity of schizophrenia.
    Dollfus S; Brazo P
    Psychopathology; 1997; 30(5):275-81. PubMed ID: 9353856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Syndromic and diagnostic heterogeneity of schizophrenia].
    Brazo P; Dollfus S
    Encephale; 1997 Apr; 23 Spec No 2():20-4. PubMed ID: 9273303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
    Conley RR; Tamminga CA; Bartko JJ; Richardson C; Peszke M; Lingle J; Hegerty J; Love R; Gounaris C; Zaremba S
    Am J Psychiatry; 1998 Jul; 155(7):914-20. PubMed ID: 9659857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A discriminant validity study of negative symptoms with a special focus on depression and antipsychotic medication.
    Lewine RR
    Am J Psychiatry; 1990 Nov; 147(11):1463-6. PubMed ID: 1977328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing negative symptoms and extrapyramidal symptoms in schizophrenia: workshop report.
    Kane JM; Dauphinais D; Barnes TR; Adler LA; Rifkin A
    Psychopharmacol Bull; 1993; 29(1):45-9. PubMed ID: 8104351
    [No Abstract]   [Full Text] [Related]  

  • 6. [Increased blink rate in schizophrenic patients].
    Mackert A; Woyth C; Flechtner KM; Frick K
    Nervenarzt; 1990 Jul; 61(7):426-30. PubMed ID: 1975431
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
    Bobes J; Arango C; Garcia-Garcia M; Rejas J;
    J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Deficit: the value and difficulty of defining the primary or secondary character of observed symptoms].
    Petit M; Langlois S
    Encephale; 1996 Jun; 22 Spec No 2():13-8. PubMed ID: 8767036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia.
    Fenton WS; McGlashan TH
    Am J Psychiatry; 1994 Mar; 151(3):351-6. PubMed ID: 7906493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between depressive and positive symptoms in schizophrenia.
    Dollfus S; Petit M; Menard JF
    J Affect Disord; 1993 May; 28(1):61-9. PubMed ID: 8100838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency and differential diagnosis of depressive syndromes in schizophrenia.
    Martin RL; Cloninger CR; Guze SB; Clayton PJ
    J Clin Psychiatry; 1985 Nov; 46(11 Pt 2):9-13. PubMed ID: 2865255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia.
    Kopelowicz A; Zarate R; Tripodis K; Gonzalez V; Mintz J
    Am J Psychiatry; 2000 Jun; 157(6):987-93. PubMed ID: 10831481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Methodological constraints in evaluating anti-deficit effects].
    Boyer P; Lecrubier Y; Rein W
    Encephale; 1996 Jun; 22 Spec No 2():25-7. PubMed ID: 8767038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MMPI discriminators of deficit vs. non-deficit recent-onset schizophrenia patients.
    Subotnik KL; Nuechterlein KH; Ventura J
    Psychiatry Res; 2000 Mar; 93(2):111-23. PubMed ID: 10725528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
    Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
    Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
    Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
    J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empirical validation of primary negative symptoms: independence from effects of medication and psychosis.
    Kelley ME; van Kammen DP; Allen DN
    Am J Psychiatry; 1999 Mar; 156(3):406-11. PubMed ID: 10080556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-episode schizophrenia: the importance of early intervention and subjective tolerability.
    Kasper S
    J Clin Psychiatry; 1999; 60 Suppl 23():5-9. PubMed ID: 10625193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
    Chouinard G; Annable L; Ross-Chouinard A
    Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
    [No Abstract]   [Full Text] [Related]  

  • 20. Deficit psychopathology and a paradigm shift in schizophrenia research.
    Carpenter WT; Arango C; Buchanan RW; Kirkpatrick B
    Biol Psychiatry; 1999 Aug; 46(3):352-60. PubMed ID: 10435200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.